AusBiotech

An Australian Biotechnology 2030 Vision (the Vision) – a decadal framework for the industry – was discussed at the AusBiotech CEO Policy Forum in Canberra last week.

AusBiotech is calling for expressions of interest from members to join the AusMedtech 2020 programme committee.

Opportunities to increase business expenditure on R&D (BERD) is on the agenda at the AusBiotech CEO Policy Forum today in Canberra.

The Queensland Women in Life Sciences Luncheon brought together over 230 guests to Brisbane, bringing recent research and initiatives to the forefront in achieving a more equal gender equality standing in life sciences.

AusBiotech is considering responding to two current consultations and is seeking member feedback into the 'Inquiry into supporting Australia's exports and attracting investment' and 'Boosting Female Founders Initiative'.

AusBiotech is commissioning research to quantify the additionality and spill-over effects of the R&D Tax Incentive and urgently calls on companies to help with information.

AusBiotech is holding a Women in Life Sciences Luncheon in Queensland next week to discuss the actions being taken within our sector to address the gender imbalance faced across the industry.

Antisense Therapeutics (ASX:ANP) has provided an update on its agreement with early access provider myTomorrows to implement an ATL1103 (Early Access Program for the treatment of acromegaly patients within select countries of the European Union.

AusBiotech has recently responded to the Senate Standing Committees on Economics’ Senate Inquiry on Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019.

Nominations are now open for the AusBiotech Board as it seeks to elect one new director. The election outcome will be announced at the 2019 Annual General Meeting of AusBiotech Ltd, which will be held at the AusBiotech national conference in October.

The stability of the R&D Tax Incentive has been identified as the most important tool for increasing business expenditure on R&D (BERD). AusBiotech is developing a policy position with practical, thought-out initiatives outlining opportunities for increasing BERD within the life sciences sector, and invites members to contribute their ideas and help inform AusBiotech’s response.

AusBiotech is calling for companies to present at Australia’s premier life science investment event: Australia Biotech and Invest Partnering 2019.